

2023 年度 業績

論文 (英文)

原著

1. Shiota M, Akamatsu S, Sekine Y, Kimura H, Narita S, Fujimoto N, Terada N, Blas L, Habuchi T, Kamoto T, Momozawa Y, Eto M.
Genetic variations predicting progression with docetaxel and novel androgen-receptor pathway inhibitors.
Cancer Sci. 2023 Jan 5. doi: 10.1111/cas.15718.
2. Shiota M, Tatarano S, Kamoto T, Matsuyama H, Sakai H, Igawa T, Kamba T, Fujimoto N, Sekine Y, Kimura H, Narita S, Terada N, Momozawa Y, Akamatsu S, Habuchi T, Yokomizo A, Naito S, Eto M.
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study.
Endocr Relat Cancer. 2023 Jun 1;30(7):e230044
3. Ota A, Kawai M, Kudo Y, Segawa J, Hoshi M, Kawano S, Yoshino Y, Ichihara K, Shiota M, Fujimoto N, Matsunaga T, Endo S, Ikari A.
Artepillin C overcomes apalutamide resistance through blocking androgen signaling in prostate cancer cells.
Arch Biochem Biophys. 2023 Feb;735:109519.
4. Harada K, Miyake H, Furukawa J, Fujimoto N, Fujisawa M.
Utility of prognostic prediction by early assessment of response to combined treatment with nivolumab plus ipilimumab in patients with treatment-naïve metastatic renal cell carcinoma.
Int J Urol. 30(9):798-800, 2023
5. Hara T, Furukawa J, Shiraishi Y, Okamura Y, Bando Y, Terakawa T, Harada K, Nakano Y, Fujisawa M.
Impact of cytoreductive nephrectomy prior to combination therapy of ipilimumab plus nivolumab in metastatic renal cell carcinoma.
Int J Urol. 30(9):746-752, 2023

6. Miyake H, Kakei Y, Nakano Y, Terakawa T, Miyakoda K, Harada K, Fujisawa M.
Efficacy and safety of apalutamide in patients with metastatic castration-resistant prostate cancer (GENESIS): protocol for a multicentre, open-label, single-arm clinical trial.
BMJ Open. 29;13(3):e070173, 2023
7. Tobe T, Terakawa T, Hara T, Ueki H, Shiraishi Y, Wakita N, Okamura Y, Bando Y, Furukawa J, Nakano Y, Harada K, Fujisawa M.
The Efficacy of Presurgical Therapy With Avelumab and Axitinib for Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus.
Clin Genitourin Cancer. 21(5):613.e1-613.e6, 2023
8. Harada K, Sato R, Bando Y, Sano A, Matsushita Y, Tamura K, Terakawa T, Furukawa J, Fujimoto N, Fujisawa M, Miyake H.
Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan.
Int J Urol. 30(9):772-777, 2023
9. Tomisaki I, Harada M, Sakano S, Terado M, Hamasuna R, Harada S, Matsumoto H, Akasaka S, Nagata Y, Minato A, Harada K, Fujimoto N.
Association Between Body Mass Index and Outcomes in Patients With Urothelial Carcinoma Treated With Pembrolizumab.
Anticancer Res. 43(1):269-274, 2023
10. Tomisaki I, Harada M, Sakano S, Terado M, Hamasuna R, Harada S, Matsumoto H, Akasaka S, Nagata Y, Minato A, Harada K, Fujimoto N.
Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.
Int J Urol. 30(9):738-745, 2023
11. Higuchi S, Matsugaki R, Tomisaki I, Fushimi K, Matsuda S, Saeki S.
Effect of Early Postoperative Rehabilitation on Length of Hospital Stay after Robot-assisted Radical Prostatectomy.
Prog Rehabil Med. 8:20230023. 2023

12. Yasuda M, Takahashi S, Miyazaki J, Wada K, Kobayashi K, Matsumoto M, Hayami H, Yamamoto S, Kiyota H, Sato J, Matsumoto T, Yotsuyanagi H, Hanaki H, Masumori N, Hiyama Y, Nishiyama H, Kimura T, Yamada H, Matsumoto K, Ishikawa K, Togo Y, Tanaka K, Sadahira T, Inokuchi J, Hamasuna R, Ito K, Hirayama H, Hayashi K, Kurimura Y, Kadena H, Ito S, Shiono Y, Maruyama T, Ito M, Hatano K, Chokyu H, Ihara H, Uno S, Monden K, Yokoyama T, Kano M, Kaji S, Kawahara M, Sumii T, Tojo T, Hosobe T, Naito K, Kawai S, Nishimura H, Izumitani M, Yoh M, Matsumura M, Fujita R, Takayama K, Hara M, Nishi S.
The third nationwide surveillance of antimicrobial susceptibility against *Neisseria gonorrhoeae* from male urethritis in Japan, 2016-2017.
J Infect Chemother. 29: 1011-1016, 2023.
13. Minato A, Kimuro R, Ohno D, Tanigawa K, Kuretake K, Matsukawa T, Takaba T, Jojima K, Harada M, Higashijima K, Nagata Y, Tomisaki I, Harada K, Fujimoto N, Miyamoto H.
Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma.
Early Experience in the Real World. Anticancer Res. 43: 4055-4060, 2023.
14. Minato A, Kudo Y, Noguchi H, Kohi S, Hasegawa Y, Sato N, Hirata K, Fujimoto N.
Receptor for hyaluronic acid-mediated motility (RHAMM) is associated with prostate cancer migration and poor prognosis.
Cancer Genomics Proteomics. 20(2): 203-210, 2023.
15. Furubayashi N, Minato A, Negishi T, Sakamoto N, Song Y, Hori Y, Tomoda T, Hiroyuki M, Harada M, Tamura S, Kobayashi H, Morihara K, Kuroiwa K, Seki N, Fujimoto N, Nakamura M.
Early phase persistent changes in the white blood cell fraction in patients with advanced urothelial carcinoma treated with pembrolizumab: A multicenter retrospective study.
Anticancer Res. 43(10): 4701-4708, 2023.
16. Furubayashi N, Minato A, Tomoda T, Hori Y, Kiyoshima K, Negishi T, Haraguchi Y, Koga T, Kuroiwa K, Fujimoto N, Nakamura M
Organ-specific tumor response to avelumab maintenance therapy for advanced urothelial carcinoma: A multicenter retrospective study.
Anticancer Res. 43(12): 5689-5698, 2023.

17. Nagata Y, Jojima K, Matsukawa T, Tomisaki I, Fujimoto N.
Initial-to-nadir Prostate-specific Antigen Ratio Predicts Response to First-line Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
Anticancer Res. 43: 4573-4581, 2023.
18. Nagata Y, Matsukawa T, Goto T, Teramoto Y, Jiang G, Fujimoto N, Miyamoto H.
Protective role of mineralocorticoid receptor signaling in urothelial tumorigenesis.
American Journal of Cancer Research 13: 408-418, 2023.
19. Nagata Y, Matsukawa T, Tomisaki I, Fujimoto N.
Prostate-specific Antigen Kinetics During Androgen-deprivation Therapy Predict Response to Enzalutamide in Metastatic Castration-resistant Prostate Cancer.
Anticancer Res. 43: 429-436, 2023.
20. Himura R, Kawano S, Nagata Y, Kawai M, OtaA, KudoY, YoshinoY,
Fujimoto N, Miyamoto H, Endo S, Ikari A
Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer
Chem Biol Interact. 2023 Dec 18:110840.
doi: 10.1016/j.cbi.2023.110840.
21. Yamaguchi T, Goya M, Higashijima K, Tobu S, Sato R, Tatarano S, Mukai S, Uemura KI, Tatsugami K, Tsubouchi K, Shida Y, Ishii T, Sakai H, Matsuoka H, Haga N, Eto M, Igawa T, Kamoto T, Enokida H, Shin T, Noguchi M, Fujimoto N, Saito S, Kamba T.
Real-world treatment outcomes of patients with penile cancer in the Kyushu-Okinawa area of Japan in the pre-guideline era.
Jpn J Clin Oncol. 2023 Aug 30;53(9):837-844.

総説

1. Fujimoto N, Tsubonuma Y, Nagata Y, Minato A, Tomisaki I, Harada K, Miyamoto H.
Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer.

Anticancer Res. 43: 3841-3847, 2023.

症例報告

1. Harada M, Tomisaki I, Shimajiri S, Kuretake K, Harada K, Fujimoto N.

Small cell carcinoma of the kidney treated with immune checkpoint inhibitor/tyrosine kinase inhibitor.

IJU Case Rep. 29;6(6):386-389, 2023.